NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Medicenna Therapeutics Corp (NASDAQ: MDNA)

 
MDNA Technical Analysis
5
As on 9th Jun 2023 MDNA STOCK Price closed @ 0.58 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.19 & Strong Sell for SHORT-TERM with Stoploss of 1.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MDNASTOCK Price

Open 0.59 Change Price %
High 0.60 1 Day -0.02 -3.33
Low 0.56 1 Week 0.04 7.41
Close 0.58 1 Month -0.08 -12.12
Volume 25207 1 Year -1.13 -66.08
52 Week High 1.92 | 52 Week Low 0.40
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
MDNA
Daily Charts
MDNA
Intraday Charts
Whats New @
Bazaartrend
MDNA
Free Analysis
 
MDNA Important Levels Intraday
RESISTANCE0.66
RESISTANCE0.63
RESISTANCE0.62
RESISTANCE0.60
SUPPORT0.56
SUPPORT0.54
SUPPORT0.53
SUPPORT0.50
 
MDNA Forecast May 2024
4th UP Forecast1.74
3rd UP Forecast1.37
2nd UP Forecast1.14
1st UP Forecast0.91
1st DOWN Forecast0.25
2nd DOWN Forecast0.02
3rd DOWN Forecast-0.21
4th DOWN Forecast-0.58
 
MDNA Weekly Forecast
4th UP Forecast0.98
3rd UP Forecast0.85
2nd UP Forecast0.77
1st UP Forecast0.69
1st DOWN Forecast0.47
2nd DOWN Forecast0.39
3rd DOWN Forecast0.31
4th DOWN Forecast0.18
 
MDNA Forecast2024
4th UP Forecast3.8
3rd UP Forecast2.77
2nd UP Forecast2.13
1st UP Forecast1.49
1st DOWN Forecast-0.33
2nd DOWN Forecast-0.97
3rd DOWN Forecast-1.61
4th DOWN Forecast-2.64
 
 
MDNA Other Details
Segment EQ
Market Capital 121182304.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MDNA Address
MDNA
 
MDNA Latest News
 
Your Comments and Response on Medicenna Therapeutics Corp
 
MDNA Business Profile
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. Address: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service